Non-GLP-1 Peptides for Fat Loss: What the Evidence Actually Says

Every week, compounding pharmacies and gray-market peptide sites advertise something that isn't semaglutide or tirzepatide but promises “fat loss without the GLP-1 side effects.” Four molecules dominate the marketing — AOD-9604, CJC-1295 / Ipamorelin, tesofensine, and cagrilintide — plus a tail of preclinical candidates like 5-Amino-1MQ and BPC-157. The published human evidence is not symmetric. One of these (cagrilintide) has Lancet phase 2 + NEJM phase 3a data and is being co-developed with semaglutide as CagriSema. One (tesofensine) has a 2008 Lancet phase 2 trial and a live phase 3 program in hypothalamic obesity. One (AOD-9604) has positive animal data and negative human data. One (CJC-1295 / Ipamorelin) has never been studied as a weight-loss intervention in a published RCT. The rest are either preclinical-only or are sold despite explicit FDA compounding restrictions. This article ranks every option by evidence quality, names every PMID we relied on, and tells you the magnitude you can actually expect.

The honest summary

• Cagrilintide is the only non-GLP-1 peptide with a credible Lancet phase 2 weight-loss signal. Lau 2021^[1] showed ~−10.8% body weight at 2.4 mg weekly over 26 weeks. It is being developed as CagriSema (cagrilintide + semaglutide), not as monotherapy. REDEFINE 1^[2] and REDEFINE 2^[3] read out in 2025.
• Tesofensine has 2008 Lancet phase 2 data (Astrup^[4]) showing ~−12.8 kg at 1.0 mg over 24 weeks — but it is a triple monoamine reuptake inhibitor (not a peptide), it failed its original obesity development for cardiovascular safety signals, and the only live program is Tesomet in hypothalamic obesity (Huynh 2022^[5]). Not FDA approved.
• AOD-9604 has positive animal data and a negative human weight-loss profile. The Ng synthetic-domain work^[6] and Heffernan 2001 mouse data^[7] are the original mechanistic papers. The subsequent human development at Metabolic Pharmaceuticals failed; AOD-9604 is not an approved obesity therapeutic anywhere. Compounding pharmacies still sell it for $80–$150 per month.
• CJC-1295 / Ipamorelin has no published RCT testing weight loss as an endpoint. Teichman 2006 JCEM^[8] showed CJC-1295 raised IGF-1 in healthy adults, but the paper did not measure body weight or body composition over a clinically meaningful interval. The “recomp” marketing claim is mechanistic speculation, not trial data.
• 5-Amino-1MQ and BPC-157 are preclinical only in the weight-loss context. Neelakantan 2018^[9] is the NNMT inhibitor mouse paper for 5-Amino-1MQ. BPC-157 has no published human weight-loss trial and is WADA prohibited.
• Magnitude context. Tirzepatide produced −22.5% total body weight in SURMOUNT-1^[10] at 72 weeks; semaglutide produced −14.9% in STEP-1^[11]. Even cagrilintide's ~−10.8% at 26 weeks is out-classed by the approved GLP-1s.

1. Cagrilintide — the strongest non-GLP-1 signal

Cagrilintide is Novo Nordisk's long-acting amylin analogue. Amylin is a pancreatic hormone co-secreted with insulin that slows gastric emptying and suppresses appetite via the area postrema. In the Lau 2021 Lancet phase 2 dose-finding trial^[1] (706 adults with overweight or obesity, no diabetes), cagrilintide was titrated from 0.3 mg to 4.5 mg weekly over 26 weeks, with liraglutide 3.0 mg as the active comparator. The 2.4 mg arm produced approximately −10.8% body weight at week 26; the 4.5 mg arm produced approximately −10.7%. Liraglutide 3.0 mg produced approximately −9.0%. Cagrilintide 2.4 mg therefore beat the FDA-approved-at-the-time GLP-1 head to head.

Novo's strategic decision was to co-develop cagrilintide with semaglutide rather than pursue monotherapy. The CagriSema phase 3a REDEFINE program read out in 2025. REDEFINE 1^[2] (Garvey, NEJM, 3,417 adults with obesity, 68 weeks) compared CagriSema 2.4 / 2.4 mg vs cagrilintide monotherapy vs semaglutide 2.4 mg vs placebo. CagriSema produced approximately −20.4% total body weight versus −14.9% on semaglutide alone and −11.8% on cagrilintide alone. REDEFINE 2^[3] (Davies, NEJM, T2D population) produced approximately −13.7% on CagriSema versus −3.4% on placebo. Cagrilintide as a standalone obesity therapeutic is not currently FDA approved and is not on the development path. If you are looking for “the amylin drug,” the realistic 2026 answer is CagriSema when (and if) Novo files.

2. Tesofensine — an old phase 2 hit, narrow live program

Tesofensine is a triple monoamine (serotonin, norepinephrine, dopamine) reuptake inhibitor — not a peptide, but it is constantly grouped with peptides in “non-GLP-1 fat loss” marketing. Astrup 2008 Lancet^[4] was a 24-week phase 2 trial in 203 obese adults. The 1.0 mg arm produced approximately −12.8 kg from baseline (− 9.2 kg vs placebo); the 0.5 mg arm produced approximately −11.3 kg. Heart rate increased dose-dependently, and the original NeuroSearch development was discontinued over cardiovascular and psychiatric safety signals.

The live program is Saniona's Tesomet (tesofensine 0.5 mg + metoprolol 50 mg, the beta-blocker added to blunt the heart-rate signal) in hypothalamic obesity, a rare disease with no approved pharmacotherapy. Huynh 2022 Eur J Endocrinol^[5] reported a randomized controlled trial of Tesomet in adults with hypothalamic obesity (the intended indication is now narrow). Tesofensine is not FDA approved for general obesity, and the historical CV signal means it is unlikely to be revived as a mass-market drug in the GLP-1 era.

3. AOD-9604 — animal-positive, human-negative

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (residues 177–191). Ng 2000^[6] characterized the synthetic lipolytic domain in mechanistic work. Heffernan 2001 Endocrinology^[7] showed chronic AOD-9604 administration produced lipolysis in obese mice. The peptide was advanced by Metabolic Pharmaceuticals into a human obesity development program in the early 2000s. The human phase 2 program reported no statistically significant weight loss versus placebo at the doses tested, and the company discontinued development. AOD-9604 is not FDA approved as an obesity drug; it carries Generally Recognized as Safe (GRAS) status for use as a dietary ingredient in some jurisdictions but that is not a weight-loss-efficacy claim. Compounded AOD-9604 is widely sold online for $80–$150 per month despite the negative human data.

4. CJC-1295 / Ipamorelin — no weight-loss RCT

CJC-1295 is a long-acting growth-hormone-releasing-hormone analogue; Ipamorelin is a selective ghrelin receptor agonist (GH secretagogue). The two are stacked because they raise GH / IGF-1 by complementary mechanisms. Teichman 2006 JCEM^[8] is the original CJC-1295 human pharmacokinetic / pharmacodynamic study: 21 healthy adults received single ascending doses of CJC-1295 (no DAC) and showed prolonged GH and IGF-1 elevation. The paper measured hormones, not body weight or body composition.

There is no published placebo-controlled RCT measuring weight loss or fat mass as an endpoint for either CJC-1295, Ipamorelin, or the stack. The marketing claim — modest “body recomposition” (lean mass up, fat mass down) — is downstream inference from GH / IGF-1 physiology, not direct trial evidence. Compounded CJC-1295 / Ipamorelin runs $200–$400 per month.

5. 5-Amino-1MQ, BPC-157, and the preclinical tail

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Neelakantan 2018 Biochem Pharmacol^[9] reported that selective NNMT inhibitors reversed high-fat-diet-induced obesity in mice. There are no published human trials of 5-Amino-1MQ as a weight-loss intervention. Marketing it as a peptide is also inaccurate — it is a small molecule.

BPC-157 is the body-protection compound, a pentadecapeptide derived from a sequence in gastric juice. Animal data covers gut-mucosal healing and tendon repair. There is no published human weight-loss trial. The FDA published BPC-157 on its Category 2 list of bulk drug substances that pose significant safety risks if used in compounded preparations under section 503A, and WADA prohibits it for athletes. It should not appear on any legitimate weight-loss prescription.

Other peptides sometimes marketed for fat loss — MOTS-c, Tesamorelin (only approved for HIV-associated lipodystrophy), Sermorelin, Hexarelin — either lack weight-loss trial evidence in general obesity or have indications too narrow to extrapolate.

Safety and regulatory reality

• FDA 503A Category 2 list. The FDA maintains a list of bulk drug substances that 503A compounding pharmacies are restricted from using because they pose safety risks. BPC-157 has been placed in Category 2; the agency has issued warning letters to compounders distributing it. Other peptides have similar regulatory status. The list is updated periodically — verify current status with the FDA Compounding Quality Center before any prescription decision.
• Purity. Gray-market peptide vendors are not FDA-inspected. Independent testing of peptides purchased online has repeatedly found low purity, wrong identity, or bacterial contamination.
• WADA prohibition. CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, and BPC-157 are all WADA prohibited. Athletes subject to anti-doping testing should not use these.
• Tesofensine CV signal. The phase 2 program showed dose-dependent heart-rate increase; that is the reason Tesomet pairs tesofensine with metoprolol.

Magnitude context

How to think about it

If a compounding pharmacy or clinic offers you a non-GLP-1 peptide for fat loss, three questions answer most of it:

1. Is there a published RCT with weight loss as an endpoint? If no, the marketing is mechanism, not evidence. CJC-1295 / Ipamorelin, 5-Amino-1MQ, BPC-157, and most of the “research peptide” tail fail this test.
2. If yes, how does the magnitude compare with an FDA-approved GLP-1? Cagrilintide monotherapy is ~−10.8% at 26 weeks. Tesofensine 1.0 mg is ~−12.8 kg at 24 weeks. Tirzepatide is −22.5% at 72 weeks. Even the best non-GLP-1 peptide signal loses to tirzepatide.
3. Is it on the FDA 503A Category 2 list, WADA prohibited, or sold by gray-market vendors? If any of those are true, the safety and purity arguments alone are usually disqualifying.

US-licensed compounding-pharmacy sources

For patients who decide a non-GLP-1 peptide is right for them — Sermorelin for the GH-axis, NAD+ or Glutathione for longevity, MIC+B12 for lipotropic support — the relevant question is sourcing. We list one US-licensed telehealth platform here as a reference point; readers should still discuss with their primary-care provider before initiating any peptide therapy:

• System Labs (System Laboratories, Inc.) — LegitScript-verified US telehealth with peptide and longevity treatments sourced from US compounding pharmacies. Current catalog: NAD+ injection $149/mo (first month $79), Glutathione $149/mo, MIC+B12 $89/mo, Sermorelin injection $219/mo (first month $109), oral Sermorelin $159/mo. Live-verified 2026-05-29.
• Brightmeds (Brightmeds LLC) — multi-vertical 47-state telehealth bundling GLP-1, TRT, Sermorelin, NAD+, and Glutathione under one membership portal. Named compounding-pharmacy partners (Beaker Pharmacy + Red Rock Pharmacy) and verbatim 503A/503B FDA disclosures published. Live-verified 2026-05-28.

Related research and tools

• Peptides for weight loss: the broader evidence review — the long-form companion that covers the full peptide landscape including GLP-1s, GIP, glucagon, and retatrutide
• Best oral peptides for weight loss: evidence vs hype — the oral-form companion (semaglutide oral, orforglipron, oral peptide claims)
• Buying tirzepatide as “research peptide”: the regulatory debunker — what gray-market peptide vendors actually sell and why purity / labeling cannot be trusted
• GLP-1 pipeline: survodutide, maridebart, ecnoglutide — the legitimate non-FDA-approved-yet pipeline (every compound has phase 2 or phase 3 data)
• Retatrutide vs tirzepatide: head-to-head evidence — the triple agonist that may eventually displace tirzepatide as the magnitude leader

Important disclaimer. This article is educational and does not constitute medical advice. None of the peptides discussed in sections 3–5 are FDA approved for obesity treatment. Cagrilintide is investigational and not approved as monotherapy. Tesofensine / Tesomet is not FDA approved. Decisions about obesity pharmacotherapy should be made with a licensed obesity-medicine clinician using FDA-approved options (semaglutide, tirzepatide, liraglutide, phentermine-topiramate, naltrexone-bupropion, setmelanotide for indicated populations) and current safety information. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if CagriSema receives FDA approval, the Tesomet phase 3 program in hypothalamic obesity reads out, or new RCT evidence appears for any non-GLP-1 peptide currently sold by compounding pharmacies.